BPMC240719C130000
- 0.81
- 0.000.00%
Blueprint Medicines Newsroom
Oppenheimer's Top SMID Ideas Within High-growth Themes
Oppenheimer's Best 'SMID-cap' Ideas for 2024
Blueprint Medicines(BPMC.US) Officer Sells US$1.41 Million in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Durso-Bumpus Debra sold 12,667 shares of common stock on Jul 3, 5, 2024 at an average price of $111.26 for a total value of $1.41 million. Source: Ann
Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating
Blueprint Medicines (BPMC) has an average outperform rating and price target range of $75 to $168, according to analysts polled by Capital IQ.Price: 112.41, Change: +0.71, Percent Change: +0.64
Blueprint Medicines Is Maintained at Outperform by Oppenheimer
Blueprint Medicines Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Blueprint Medicines, Raises Price Target to $125
Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $114 to $125.
Oppenheimer Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $125
Oppenheimer analyst Matthew Biegler maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and maintains the target price at $125.According to TipRanks data, the analyst has a success rate of 31.
Express News | Blueprint Medicines : Oppenheimer Raises Target Price to $125 From $114
Oppenheimer Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Raises Target Price to $125
Oppenheimer analyst Matthew Biegler maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and adjusts the target price from $114 to $125.According to TipRanks data, the analyst has a success rat
Blueprint Medicines(BPMC.US) Officer Sells US$37,012.95 in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Durso-Bumpus Debra sold 333 shares of common stock on Jun 28, 2024 at an average price of $111.15 for a total value of $37,012.95.Source: Announcement What is st
Blueprint Medicines Insiders Sell US$7.2m Of Stock, Possibly Signalling Caution
Over the past year, many Blueprint Medicines Corporation (NASDAQ:BPMC) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transaction
Expert Ratings For Blueprint Medicines
During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.Summarizing their recent assessments, the ta
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $130
Needham analyst Ami Fadia maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 43.9% and a t
Blueprint Medicines Price Target Maintained With a $130.00/Share by Needham
Blueprint Medicines Price Target Maintained With a $130.00/Share by Needham
Needham Reiterates Buy on Blueprint Medicines, Maintains $130 Price Target
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $130 price target.
Blueprint Medicines(BPMC.US) Officer Sells US$7.71 Million in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Durso-Bumpus Debra sold 74,034 shares of common stock on Jun 21, 2024 at an average price of $104.19 for a total value of $7.71 million.Source: Announcement What
Blueprint Medicines Insider Sold Shares Worth $7,713,537, According to a Recent SEC Filing
Debra Durso-Bumpus, Chief People Officer, on June 21, 2024, sold 74,034 shares in Blueprint Medicines (BPMC) for $7,713,537. Following the Form 4 filing with the SEC, Durso-Bumpus has control over a t
Form 144 | Blueprint Medicines(BPMC.US) Officer Proposes to Sell 9.23 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 21, $Blueprint Medicines(BPMC.US)$ Officer Debra Bumpus intends to sell 87,034 shares of its common stock on Jun 21, with a total market value of approximately $9.23 millio
Investing in Blueprint Medicines (NASDAQ:BPMC) a Year Ago Would Have Delivered You a 78% Gain
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. To wit, the Blueprint Medicines Corporation (NASDA
Unusual Options Activity: APA, LNG and Others Attract Market Bets, APA V/OI Ratio Reaches 420.0
EST Jun 11th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.O